Beyond market trends, investors keen on maximizing returns delve into the world of stock picking. The right selections can be instrumental in catapulting your wealth.
After finishing at $1.09 in the prior trading day, Fate Therapeutics Inc (NASDAQ: FATE) closed at $1.05, down -3.67%. In other words, the price has decreased by -$3.67 from its previous closing price. On the day, 1.51 million shares were traded. FATE stock price reached its highest trading level at $1.13 during the session, while it also had its lowest trading level at $1.05.
Ratios:
Our goal is to gain a better understanding of FATE by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 7.87 and its Current Ratio is at 7.87. In the meantime, Its Debt-to-Equity ratio is 0.34 whereas as Long-Term Debt/Eq ratio is at 0.32.
On October 27, 2025, Wedbush Upgraded its rating to Outperform which previously was Neutral but kept the price unchanged to $7.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Aug 04 ’25 when TAHL CINDY sold 9,037 shares for $1.06 per share. The transaction valued at 9,573 led to the insider holds 397,670 shares of the business.
Valamehr Bahram sold 14,466 shares of FATE for $15,396 on Aug 04 ’25. The President and CEO now owns 334,898 shares after completing the transaction at $1.06 per share. On Aug 04 ’25, another insider, TAHL CINDY, who serves as the Officer of the company, bought 9,037 shares for $1.06 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, FATE now has a Market Capitalization of 121119896 and an Enterprise Value of -15055097. For the stock, the TTM Price-to-Sale (P/S) ratio is 16.96 while its Price-to-Book (P/B) ratio in mrq is 0.52. Its current Enterprise Value per Revenue stands at -2.109 whereas that against EBITDA is 0.104.
Stock Price History:
The Beta on a monthly basis for FATE is 2.22, which has changed by -0.34337348 over the last 52 weeks, in comparison to a change of 0.15905356 over the same period for the S&P500. Over the past 52 weeks, FATE has reached a high of $2.02, while it has fallen to a 52-week low of $0.66. The 50-Day Moving Average of the stock is -14.31%, while the 200-Day Moving Average is calculated to be -7.24%.
Shares Statistics:
The stock has traded on average 2.10M shares per day over the past 3-months and 1199100 shares per day over the last 10 days, according to various share statistics. A total of 115.34M shares are outstanding, with a floating share count of 109.69M. Insiders hold about 4.91% of the company’s shares, while institutions hold 71.34% stake in the company. Shares short for FATE as of 1764288000 were 8184722 with a Short Ratio of 3.89, compared to 1761868800 on 6831984. Therefore, it implies a Short% of Shares Outstanding of 8184722 and a Short% of Float of 8.09.
Earnings Estimates
The dynamic stock of Fate Therapeutics Inc (FATE) is currently being evaluated by a team of 9.0 analysts, each contributing to its current rating.The consensus estimate for the next quarter is -$0.28, with high estimates of -$0.26 and low estimates of -$0.32.
Analysts are recommending an EPS of between -$1.1 and -$1.18 for the fiscal current year, implying an average EPS of -$1.15. EPS for the following year is -$1.16, with 9.0 analysts recommending between -$0.91 and -$1.37.
Revenue Estimates
A total of 12 analysts have provided revenue estimates for FATE’s current fiscal year. The highest revenue estimate was $7.8M, while the lowest revenue estimate was $5.28M, resulting in an average revenue estimate of $6.36M. In the same quarter a year ago, actual revenue was $13.63M
